EpiCeram contains a balanced ratio of ceramides, free fatty acids, and cholesterol, which are essential lipids for total skin barrier repair; they mimic the lipid concentration found in the skin.

CINCINNATI--(BUSINESS WIRE)--Symplmed announced today that it has entered into an agreement with PuraCap® Pharmaceutical LLC to distribute a new product, EpiCeram-L™ Lip Care, through Symplmed’s ...

DENVER -- Ceragenix Pharmaceuticals, a biopharmaceutical company focused on infectious disease and dermatology, provided the following update regarding its ongoing efforts to commercialize EpiCeram®. ...

Pediapharm to Register, Market and Sell in Canada. Denver, CO and Montreal, QC -- February 25, 2009 -- Ceragenix Pharmaceuticals, Inc.("Ceragenix") (OTCBB:CGXP), a medical device company focused on ...

PISCATAWAY, N.J., Aug. 15, 2017 /PRNewswire/ -- PuraCap ® Pharmaceutical today introduces the EpiCeram ® Controlled Release Skin Barrier Emulsion Quad Pack which contains 400 grams of eczema relief.

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

EpiCeram Airless Pump Now Available PuraCap announced the introduction of EpiCeram Airless Pump, the latest addition to the EpiCeram line. EpiCeram is a controlled-release skin barrier emulsion that ...

This is the first milestone granted in $3.5M deal to commercialize nonsteroidal skincare cream. Ceragenix Pharmaceuticals received a $1.5 million milestone payment from Dr. Reddy’s Laboratories ...

DENVER Dr. Reddy’s Laboratories has inked an exclusive distribution and supply agreement with the biotech company Ceragenix Pharmaceuticals to commercialize EpiCeram, a topical cream used for treating ...

PuraCap(TM) Pharmaceutical today announced the newest addition to the EpiCeram(R) product line, the EpiCeram(R) 225g Airless Pump. The unique airless pump gives patients more EpiCeram(R) to treat any ...

April 18, 2006 — The US Food and Drug Administration (FDA) has approved an integrated insulin pump and continuous glucose monitoring system for the management of type 1 and type 2 diabetes mellitus; 3 ...

This was a non-controlled (all participants treated), open label (parents of participants and study staff all knew the treatment status of all children), phase 1 study. The trial was registered with ...